

## **Publications in Peer-Reviewed Journals:**

*SCiAN's best-in-class trial design, data management and biostatistics support acknowledged*

### **FOR IMMEDIATE RELEASE**

TORONTO, ON – September 02, 2014 – SCiAN Services, Inc., a North American Clinical Data Management – Biostatistics CRO and EDC solution provider acknowledges the following 3 successful publications in peer-reviewed journals in 2014:

Hauser RA, Olanow CW, Kieburtz KD, Pourcher E, Docu-Axelerad A, Lew M, Kozyolkin O, Neale A, Resburg C, Meya U, Kenney C, Bandak S. “*Tozedenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomized trial*”. **The Lancet Neurology**, 2014 Vol. 13 No. 8 pp. 767-776

Bottcher B, Laterza RM, Wildt, L, Seufert RJ, Buhling KJ, Singer CF, Hill W, Griffin P, Jilma B, Schulz M, Smith RP. “*A first-in-human study of PDC31 (prostaglandin F2a receptor inhibitor) in primary dysmenorrhea*”. **Human Reproduction** 2014 Vol. 0 No. 0 pp. 1-9 doi: 10.1093/humrep/deu205.

Zaltzman JS, Lai V, Schulz M, Moon KH, Cherney DZ. “*A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers*”. **Transplant International**, 2014 doi: 10.1111/tri.12435.

In recognizing the sponsors on their accomplishment, Dr. Miklos Schulz, President and CEO of SCiAN Services, Inc. said: “we also want to thank Biotie Therapies, PDC Biotech, and Astellas Global for the opportunity of being part of their clinical development program and extend our continuous commitment to supporting their innovative program. The professional team at SCiAN shares their excitement in having been an integral part and contributor of best-in-class trial design, data management and biostatistics.”

### **About SCiAN**

SCiAN Services is a North American leading Study Design – Clinical Data Management – Biostatistics – Pharmacovigilance CRO and EDC solution provider. Drug developers (Biotech / Biopharma, and pharmaceutical companies) rely on SCiAN's 27 years of experience in IND stage clinical trials phases Ib - III. SCiAN's therapeutic area expertise developed in over 650 clinical trials includes oncology, CNS, infectious diseases, inflammatory / autoimmune diseases, diabetes, etc. The company's service depth is further backed by its industry renowned EDC<sup>PRO</sup> platform, custom developed for small to medium size drug development companies and their CROs.

**For more information, please contact:**

SCiAN Services Incl.  
Jasna Szwagiel  
Corporate Communication  
Email: [jszwagiel@scian.com](mailto:jszwagiel@scian.com)  
URL: [www.scian.com](http://www.scian.com)

SCiAN Services, Inc.  
Toronto, ON Canada M8X 1X3  
Ph: 416 231 8008  
Fx: 416 231 1422

SCiAN Services USA, Inc.  
King of Prussia, PA 19406  
Ph: 610-945-1763  
Fx: 610-945-2001

SCiAN Services USA, Inc.  
Walnut Creek, CA 94597  
Ph: 925-407-2069  
Fx: 925-407-4769

Toll-free (U.S. & Canada): 1 800 915 9315